Literature DB >> 26752979

Recruitment techniques for alcohol pharmacotherapy clinical trials: A cost-benefit analysis.

D Andrew Tompkins1, Jessica A Sides2, Joseph A Harrison1, Eric C Strain1.   

Abstract

OBJECTIVES: Alcohol use disorders (AUDs) represent a large public health burden with relatively few efficacious pharmacotherapies. Randomized controlled trials (RCTs) for new AUD therapies can be hampered by ineffective recruitment, leading to increased trial costs. The current analyses examined the effectiveness of recruitment efforts during two consecutive outpatient RCTs of novel AUD pharmacotherapies conducted between 2009 and 2012.
METHODS: During an initial phone screen, participants identified an ad source for learning about the study. Qualified persons were then scheduled for in-person screens. The present analyses examined demographic differences amongst the eight ad sources utilized. Recruitment effectiveness was determined by dividing the number of persons meeting criteria for an in-person screen by the total number of callers from each ad source. Cost-effectiveness was determined by dividing total ad source cost by number of screens, participants randomized, and completers.
RESULTS: 1,813 calls resulted in 1,005 completed phone screens. The most common ad source was TV (34%), followed by print (29%), word-of-mouth (11%), flyer (8%), internet (5%), radio (5%), bus ad (2%), and billboard (1%). Participants reporting bus ads (46%), billboard (44%), or print ads (34%) were significantly more likely than the other sources to meet criteria to be scheduled for in-person screens. The most cost-effective ad source was print ($2,506 per completer), while bus ad was the least cost-effective ($13,376 per completer).
CONCLUSIONS: Recruitment in AUD RCTs can be successful using diverse advertising methods. The present analyses favored use of print ads as most cost-effective.

Entities:  

Keywords:  advertisement methods; alcohol use disorders; clinical trials; recruitment

Year:  2015        PMID: 26752979      PMCID: PMC4704795          DOI: 10.1097/ADT.0000000000000047

Source DB:  PubMed          Journal:  Addict Disord Their Treat        ISSN: 1531-5754


  15 in total

1.  Predictors of cessation pharmacotherapy use among black and non-Hispanic white smokers.

Authors:  Katherine K Ryan; Elizabeth Garrett-Mayer; Anthony J Alberg; Kathleen B Cartmell; Matthew J Carpenter
Journal:  Nicotine Tob Res       Date:  2011-04-04       Impact factor: 4.244

Review 2.  The efficacy of disulfiram: a review of outcome studies.

Authors:  J C Hughes; C C Cook
Journal:  Addiction       Date:  1997-04       Impact factor: 6.526

3.  Use of exclusion criteria in selecting research subjects and its effect on the generalizability of alcohol treatment outcome studies.

Authors:  K Humphreys; C Weisner
Journal:  Am J Psychiatry       Date:  2000-04       Impact factor: 18.112

4.  Issues in the development of subject recruitment strategies and eligibility criteria in multisite trials of matching.

Authors:  A Zweben; D M Donovan; C L Randall; D Barrett; K Dermen; E Kabela; B McRee; R Meyers; C Rice; D Rosengren
Journal:  J Stud Alcohol Suppl       Date:  1994-12

5.  Conducting research with racial/ethnic minorities: methodological lessons from the NIDA Clinical Trials Network.

Authors:  A Kathleen Burlew; Jerren C Weekes; La'Trice Montgomery; Daniel J Feaster; Michael S Robbins; Carmen L Rosa; Lesia M Ruglass; Kamilla L Venner; Li-Tzy Wu
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

Review 6.  Medications development to treat alcohol dependence: a vision for the next decade.

Authors:  Raye Z Litten; Mark Egli; Markus Heilig; Changhai Cui; Joanne B Fertig; Megan L Ryan; Daniel E Falk; Howard Moss; Robert Huebner; Antonio Noronha
Journal:  Addict Biol       Date:  2012-03-28       Impact factor: 4.280

7.  Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence.

Authors:  Kirsten C Morley; Maree Teesson; Claudia Sannibale; Paul S Haber
Journal:  Drug Alcohol Rev       Date:  2009-05

8.  A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.

Authors:  Joanne B Fertig; Megan L Ryan; Daniel E Falk; Raye Z Litten; Margaret E Mattson; Janet Ransom; William J Rickman; Charles Scott; Domenic Ciraulo; Alan I Green; Nassima A Tiouririne; Bankole Johnson; Helen Pettinati; Eric C Strain; Eric Devine; Mary F Brunette; Kyle Kampman; David A Tompkins; Robert Stout
Journal:  Alcohol Clin Exp Res       Date:  2012-02-10       Impact factor: 3.455

9.  "Who gets in?" Recruitment and screening processes of outpatient substance abuse trials.

Authors:  Shelly L Sayre; Mark Evans; Patricia S Hokanson; Joy M Schmitz; Angela L Stotts; Patricia Averill; John Grabowski
Journal:  Addict Behav       Date:  2004-02       Impact factor: 3.913

10.  A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence.

Authors:  Raye Z Litten; Megan L Ryan; Joanne B Fertig; Daniel E Falk; Bankole Johnson; Kelly E Dunn; Alan I Green; Helen M Pettinati; Domenic A Ciraulo; Ofra Sarid-Segal; Kyle Kampman; Mary F Brunette; Eric C Strain; Nassima A Tiouririne; Janet Ransom; Charles Scott; Robert Stout
Journal:  J Addict Med       Date:  2013 Jul-Aug       Impact factor: 3.702

View more
  2 in total

1.  Making pharmacotherapy trials for substance use disorder more efficient: Leveraging real-world data capture to maximize power and expedite the medication development pipeline.

Authors:  Ryan W Carpenter; Lindsay M Squeglia; Noah N Emery; Erin A McClure; Kevin M Gray; Robert Miranda; Rachel L Tomko
Journal:  Drug Alcohol Depend       Date:  2020-02-05       Impact factor: 4.492

2.  The Treatment In Morning versus Evening (TIME) study: analysis of recruitment, follow-up and retention rates post-recruitment.

Authors:  David A Rorie; Robert W V Flynn; Isla S Mackenzie; Thomas M MacDonald; Amy Rogers
Journal:  Trials       Date:  2017-11-23       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.